Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Medicine, Oncology,
tumor mutational burden   immune checkpoint inhibition   metastatic melanoma   real-world study   biomarkers   efficacy prediction   BRAF status  

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...

GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers

Medicine, Rheumatology and Immunology, Basic Medical Sciences, Oncology, Life Sciences, Biochemistry, Immunology,
GRIN2A mutation   cancer immunotherapy   immune checkpoint inhibitors   tumor mutational burden   tumor-infiltrating immune cells  

GRIN2A Mutations as a Novel Indicator for Stratifying Beneficiaries of Immune Checkpoint Inhibitors in Various Cancers Background Immune checkpoint inhibitors (ICIs) therapy, which modulates the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death (ligand) 1 (PD-(L)1) pathways, has made revolutionary progress in treating v...